Related Experiment Videos
[Angiogenesis in bladder: prognosis indicator and therapeutic target]
E Chabannes1, S Bernardini, H Wallerand
1Service d'Urologie, Hôpital Saint-Jacques, Besançon, France. echabannes@chu-besancon.fr
Summary
Angiogenesis, the formation of new blood vessels, fuels bladder tumor growth. Targeting this process with therapies like suramine shows promise for effective and safe bladder cancer treatment.
Area of Science:
- Oncology
- Vascular Biology
Context:
- Angiogenesis is crucial for solid tumor growth and metastasis.
- Tumor-associated cells and tumor cells synthesize angiogenic factors.
- Basic Fibroblast Growth Factor (bFGF) and Vascular Endothelial Growth Factor (VEGF) are key in bladder tumor angiogenesis.
Purpose:
- To explore the role of angiogenesis in bladder tumors.
- To evaluate angiogenic factors (bFGF, VEGF) as potential biomarkers.
- To assess the efficacy and safety of anti-angiogenic therapies for bladder cancer.
Summary:
- Microvascular density (MVD) is an indicator of bladder tumor recurrence and survival.
- VEGF expression in tumors and bodily fluids may predict superficial bladder tumor progression.
- Urinary bFGF levels are elevated in bladder cancer patients but lack specificity.
Impact:
- Inhibiting tumor angiogenesis is a viable therapeutic strategy for bladder cancer.
- Intravesical suramine and TNP-470 (a fumagillin analogue) demonstrate promising efficacy and safety.
- This research supports the development of novel anti-angiogenic treatments for bladder tumors.